Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 3

recruiting
3 987
countries
28
conditions
2 109

701 trials match your criteria

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327

Metabolic dysfunction-associated liver disease

Recruiting

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100

Hepatic cirrhosis

Recruiting

Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.